Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 4, 2015

Primary Completion Date

February 6, 2019

Study Completion Date

July 4, 2019

Conditions
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

Continuous intravenous infusion over four weeks per treatment cycle

Trial Locations (16)

460-0001

National Hospital Organization Nagoya Medical Center, Nagoya

466-8560

Nagoya University Hospital, Nagoya

812-8582

Kyushu University Hospital, Fukuoka

371-0821

Gunmaken Saiseikai Maebashi Hospital, Maebashi

003-0006

Sapporo Hokuyu Hospital, Sapporo

650-0017

Kobe University Hospital, Kobe

232-8555

Kanagawa Childrens Medical Center, Yokohama

852-8501

Nagasaki University Hospital, Nagasaki

951-8566

Niigata Cancer Center Hospital, Niigata

700-8558

Okayama University Hospital, Okayama

534-0021

Osaka City General Hospital, Osaka

545-8586

Osaka Metropolitan University Hospital, Osaka

330-8777

Saitama Childrens Medical Center, Saitama-shi

329-0498

Jichi Medical University Hospital, Shimotsuke-shi

104-0045

National Cancer Center Hospital, Chuo-ku

157-8535

National Center for Child Health and Development, Setagaya-ku

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Amgen Astellas Biopharma K.K.

INDUSTRY

lead

Amgen

INDUSTRY